Just back from a frenetic and fantastic ASH, but still have news to share from ASCO.
But first here is a link to our poster on our free second opinion program:
4716 An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)
Here are two more of my reviews of the 10 ten abstracts from ASCO 2019:
Surviving CLL is only part of the story if we are going to succumb to second cancers. This ASCO abstract studies second cancers in CLL patients on ibrutinib or acalabrutib.
In my #7 of the top 10 CLL abstracts from ASH, I review the encouraging data on the benefits of transplants for Richter’s Transformations.
We are all in this together.
Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc